(Q37729160)

22 August 2017

1 reference

title

Renal toxicity associated with tenofovir use. (English)

1 reference

22 August 2017

1 reference

0 references

0 references

4

Vincent Soriano

1 reference

22 August 2017

Sonia Rodriguez-Nóvoa

series ordinal

1

1 reference

22 August 2017

Elena Alvarez

series ordinal

2

1 reference

22 August 2017

Pablo Labarga

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Drug Safety

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

4

1 reference

22 August 2017

545-559

1 reference

Cidofovir-induced end-stage renal failure

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Mechanism of active renal tubular efflux of tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir renal toxicity targets mitochondria of renal proximal tubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Rosiglitazone reverses tenofovir-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Chronic renal failure among HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Antiretroviral therapy with tenofovir is associated with mild renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Renal lesions in HIV-1-positive patient treated with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Acute renal failure in an AIDS patient on tenofovir: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Acquired Fanconi's syndrome associated with tenofovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Severe hypokalemia and tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Fanconi's syndrome in HIV+ adults: report of three cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Longitudinal study on mitochondrial effects of didanosine-tenofovir combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Pharmacogenetics of tenofovir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir-associated renal and bone toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627458

10.1517/14740331003627458

21 January 2018

Identifiers

DOI

1 reference

release_va4hgm5j4zd53fpbdyqgjbex4i

22 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/va4hgm5j4zd53fpbdyqgjbex4i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference